Aardvark Therapeutics Financials
Aardvark Therapeutics (AARD) reported $5.1M in revenue for fiscal year 2025, up 112.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is funding a sharp R&D expansion, while product revenue remains far too small to carry the cash burn.
From FY2024 to FY2025, revenue added only$2.7M while operating cash burn worsened by$36.1M because R&D spend rose by$31.6M ; that combination shows 2025 functioned more like an investment year than a self-funding commercial year. With operating cash flow at-$54.2M and year-end cash of$47.1M , the balance sheet still depends more on funding access than on internally generated cash.
The net loss of
The balance sheet is liquid near term—
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Aardvark Therapeutics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Aardvark Therapeutics's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 27/100.
Aardvark Therapeutics's revenue surged 112.9% year-over-year to $5.1M, reflecting rapid business expansion. This strong growth earns a score of 98/100.
Aardvark Therapeutics carries a low D/E ratio of 0.10, meaning only $0.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 80/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 10.61, Aardvark Therapeutics holds $10.61 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 97/100.
Aardvark Therapeutics's reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 2/100.
Aardvark Therapeutics posts a -54.0% return on equity (ROE), meaning it loses $54 for every $100 of shareholders' equity. This results in a returns score of 27/100.
Aardvark Therapeutics scores 6.42, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($149.3M) relative to total liabilities ($10.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Aardvark Therapeutics passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Aardvark Therapeutics reported a net loss of $57.6M while operations used $54.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Aardvark Therapeutics generated $5.1M in revenue in fiscal year 2025. This represents an increase of 112.9% from the prior year.
Aardvark Therapeutics's EBITDA was -$62.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 175.3% from the prior year.
Aardvark Therapeutics reported -$57.6M in net income in fiscal year 2025. This represents a decrease of 179.7% from the prior year.
Aardvark Therapeutics earned -$2.93 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Aardvark Therapeutics recorded an outflow of $54.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 198.2% from the prior year.
Aardvark Therapeutics held $47.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Aardvark Therapeutics's ROE was -54.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Aardvark Therapeutics invested $48.9M in research and development in fiscal year 2025. This represents an increase of 181.8% from the prior year.
Aardvark Therapeutics invested $95K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 12.8% from the prior year.
Not reported for fiscal year 2025.
AARD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 |
|---|---|---|---|
| Revenue | $4.1M | $5.1M+112.9% | $2.4M |
| R&D Expenses | $55.1M | $48.9M+181.8% | $17.4M |
| SG&A Expenses | $18.9M | $13.8M+159.9% | $5.3M |
| Operating Income | -$74.0M | -$62.7M-175.3% | -$22.8M |
| Income Tax | N/A | $0 | $0 |
| Net Income | -$69.9M | -$57.6M-179.7% | -$20.6M |
| EPS (Diluted) | — | -$2.93 | -$5.15 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AARD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 |
|---|---|---|
| Total Assets | $117.2M+51.2% | $77.5M |
| Current Assets | $111.9M+50.9% | $74.1M |
| Cash & Equivalents | $47.1M-23.7% | $61.6M |
| Total Liabilities | $10.5M-92.0% | $132.2M |
| Current Liabilities | $10.5M+114.1% | $4.9M |
| Total Equity | $106.6M+295.1% | -$54.6M |
| Retained Earnings | -$115.9M-98.7% | -$58.3M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
AARD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 |
|---|---|---|---|
| Operating Cash Flow | -$69.4M | -$54.2M-199.5% | -$18.1M |
| Capital Expenditures | N/A | $95K-12.8% | $109K |
| Free Cash Flow | N/A | -$54.3M-198.2% | -$18.2M |
| Investing Cash Flow | $116.5M | -$49.7M-314.0% | -$12.0M |
| Financing Cash Flow | $711K | $89.2M+8.9% | $82.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AARD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 |
|---|---|---|
| Operating Margin | -1220.6% | -943.9% |
| Net Margin | -1120.7% | -852.9% |
| Return on Equity | -54.0% | N/A |
| Return on Assets | -49.1%-22.6pp | -26.6% |
| Current Ratio | 10.61-4.4x | 15.05 |
| Debt-to-Equity | 0.10 | N/A |
| FCF Margin | -1056.0% | -753.8% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Aardvark Therapeutics Ranks
Frequently Asked Questions
What is Aardvark Therapeutics's annual revenue?
Aardvark Therapeutics (AARD) reported $5.1M in total revenue for fiscal year 2025. This represents a 112.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Aardvark Therapeutics's revenue growing?
Aardvark Therapeutics (AARD) revenue grew by 112.9% year-over-year, from $2.4M to $5.1M in fiscal year 2025.
Is Aardvark Therapeutics profitable?
No, Aardvark Therapeutics (AARD) reported a net income of -$57.6M in fiscal year 2025.
What is Aardvark Therapeutics's EBITDA?
Aardvark Therapeutics (AARD) had EBITDA of -$62.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aardvark Therapeutics's return on equity (ROE)?
Aardvark Therapeutics (AARD) has a return on equity of -54.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Aardvark Therapeutics's free cash flow?
Aardvark Therapeutics (AARD) recorded an outflow of $54.3M in free cash flow during fiscal year 2025. This represents a -198.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aardvark Therapeutics's operating cash flow?
Aardvark Therapeutics (AARD) recorded an outflow of $54.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Aardvark Therapeutics's total assets?
Aardvark Therapeutics (AARD) had $117.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Aardvark Therapeutics's capital expenditures?
Aardvark Therapeutics (AARD) invested $95K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Aardvark Therapeutics spend on research and development?
Aardvark Therapeutics (AARD) invested $48.9M in research and development during fiscal year 2025.
What is Aardvark Therapeutics's current ratio?
Aardvark Therapeutics (AARD) had a current ratio of 10.61 as of fiscal year 2025, which is generally considered healthy.
What is Aardvark Therapeutics's debt-to-equity ratio?
Aardvark Therapeutics (AARD) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aardvark Therapeutics's return on assets (ROA)?
Aardvark Therapeutics (AARD) had a return on assets of -49.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Aardvark Therapeutics's cash runway?
Based on fiscal year 2025 data, Aardvark Therapeutics (AARD) had $47.1M in cash against an annual operating cash burn of $54.2M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Aardvark Therapeutics's Altman Z-Score?
Aardvark Therapeutics (AARD) has an Altman Z-Score of 6.42, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Aardvark Therapeutics's Piotroski F-Score?
Aardvark Therapeutics (AARD) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aardvark Therapeutics's earnings high quality?
Aardvark Therapeutics (AARD) reported a net loss of $57.6M while operations used $54.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Aardvark Therapeutics?
Aardvark Therapeutics (AARD) scores 55 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.